| Species |
Human |
| Protein Construction |
Oncostatin M/OSM (Ala26-Arg221)_x000D_
Accession # P13725 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 0.1 EU per μg by the LAL method. |
| Biological Activity |
Measured in a cell proliferation assay using TF1 human erythroleukemic cells.The ED50 for this effect is 0.31ng/mL. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
23.24 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
OSM is a pleiotropic cytokine that initiates its biological activities by binding to specific cell surface receptors. Inhibits the proliferation of a number of tumor cell lines. Stimulates proliferation of AIDS-KS cells. It regulates cytokine production, including IL-6, G-CSF and GM-CSF from endothelial cells. Uses both type I OSM receptor (heterodimers composed of LIFR and IL6ST) and type II OSM receptor (heterodimers composed of OSMR and IL6ST). Involved in the maturation of fetal hepatocytes, thereby promoting liver development and regeneration. |
| Synonyms |
Oncostatin M; OSM; MGC20461 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
